Cellular Stress Targeted By Black Belt TX-Praxis Biotech Partnership

A New Mechanism Of Action In Cancer

A strategic partnership active in the hot area of understanding the tumor micro-environment in order to develop new cancer drugs has been formed by two new biotechs, the UK’s Black Belt TX and the US’s Praxis Biotech.  

Black belt
The fight against cancer requires expertise in numerous areas. • Source: Shutterstock

Just a little over a year after being spun out of a Roche acquisition target, the fledgling UK biotech, Black Belt TX Ltd., says it will form a strategic partnership with an early-stage US firm, Praxis Biotech, on developing anticancer drugs which modulate cellular stress response pathways in the tumor microenvironment, potentially a new mode of action.

It is one of the first collaborations entered into by Black Belt TX, a biotech set up with the backing of the Belgian venture capital firm, DROIA Oncology Ventures, which also backed Tusk Therapeutics Ltd

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Immuno-oncology

More from Anticancer